Waverly Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Waverly Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-19,713	Closed	-$150K	–	986
2024 Q3	$150K	Hold	19,713	–	–	﹤0.01%	787
2024 Q2	$122K	Buy	19,713 +2,284	+13%	+$12.6K	﹤0.01%	789
2024 Q1	$88.5K	Sell	17,429 -7,450	-30%	-$41.9K	﹤0.01%	678
2023 Q4	$149K	Hold	24,879	–	–	0.01%	440
2023 Q3	$176K	Hold	24,879	–	–	0.01%	389
2023 Q2	$175K	Hold	24,879	–	–	0.01%	349
2023 Q1	$207K	Hold	24,879	–	–	0.01%	274
2022 Q4	$286K	Hold	24,879	–	–	0.02%	226
2022 Q3	$313K	Sell	24,879 -5,050	-17%	-$65K	0.02%	192
2022 Q2	$317K	Buy	29,929 +50	+0.2%	+$516	0.03%	162
2022 Q1	$486K	Hold	29,879	–	–	0.04%	122
2021 Q4	$532K	Hold	29,879	–	–	0.05%	114
2021 Q3	$369K	Hold	29,879	–	–	0.03%	152
2021 Q2	$483K	Hold	29,879	–	–	0.04%	116
2021 Q1	$417K	Buy	29,879 +7,450	+33%	+$76.8K	0.04%	111
2020 Q4	$206K	Sell	22,429 -1,000	-4%	-$5.16K	0.02%	148
2020 Q3	$89K	Hold	23,429	–	–	0.01%	140
2020 Q2	$108K	Hold	23,429	–	–	0.01%	150
2020 Q1	$47K	Buy	23,429 +1,000	+4%	+$2.75K	0.01%	142
2019 Q4	$67K	Hold	22,429	–	–	0.01%	138
2019 Q3	$64K	Hold	22,429	–	–	0.01%	131
2019 Q2	$85K	Hold	22,429	–	–	0.01%	126
2019 Q1	$183K	Hold	22,429	–	–	0.03%	120
2018 Q4	$181K	Hold	22,429	–	–	0.03%	109
2018 Q3	$171K	Buy	+22,429	New	+$151K	0.03%	184
2018 Q1	–	Sell	-12,132	Closed	-$60K	–	198
2017 Q4	$60K	Buy	+12,132	New	+$58.8K	0.01%	244
2015 Q4	–	Sell	-3,762	Closed	-$43K	–	154
2015 Q3	$43K	Hold	3,762	–	–	0.03%	153
2015 Q2	$56K	Hold	3,762	–	–	0.03%	123
2015 Q1	$34K	Buy	+3,762	New	+$39K	0.02%	152
2014 Q4	–	Sell	-10,000	Closed	-$98K	–	443
2014 Q3	$98K	Sell	10,000 -10,000	-50%	-$123K	0.05%	141
2014 Q2	$255K	Hold	20,000	–	–	0.11%	95
2014 Q1	$212K	Sell	20,000 -17,600	-47%	-$188K	0.1%	96
2013 Q4	$286K	Buy	37,600 +10,000	+36%	+$63.3K	0.1%	117
2013 Q3	$201K	Hold	27,600	–	–	0.1%	100
2013 Q2	$43K	Buy	+27,600	New	+$47.6K	0.02%	97

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Waverly Advisors's BCRX Position: Q4 2024 in Review

Waverly Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2024, closing a stake of 19,713 shares — an estimated $150K sold.

Waverly Advisors first reported a position in BCRX in Q2 2013 and held it in 35 quarters. The position peaked at $532K in Q4 2021. 258 funds tracked by Wall St. Rank hold BCRX as of Q4 2024.

Waverly Advisors reported no remaining BioCryst Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Waverly Advisors sold 19,713 BioCryst Pharmaceuticals shares in Q4 2024, an estimated $150K.
Waverly Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 35 quarters.
Waverly Advisors's BioCryst Pharmaceuticals position peaked at $532K in Q4 2021.
258 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2024.

Based on Waverly Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.